To include your compound in the COVID-19 Resource Center, submit it here.

Aevi's AEVI-001 misses in Phase II for children with ADHD

Aevi Genomic Medicine Inc. (NASDAQ:GNMX) said AEVI-001 missed the primary endpoint in both Parts A and B

Read the full 172 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE